AZD6738 for Patients With Progressive MDS or CMML
This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .
A Phase Ib/II Study of AZD6738 for Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
- ClinicalTrials.gov Identifier: NCT03770429
- Protocol Number: 18-477
- Principal Investigator: Malgorzata McMasters
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required